Protea Biosciences Group Inc Common Stock (OB:PRGB)
Business Focus: N/A
Oct 10, 2017 09:30 am ET
Protea Announces Clinical Assay Development Plans
MORGANTOWN, W.Va., Oct. 10, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") announced today that it plans to develop clinical screening assays in various areas of oncology. The assays shall be developed on Bruker's rapifleX™ MALDI Tissuetyper™ using Protea's proprietary histology guided mass spectrometry workflows and expertise.
Aug 22, 2017 09:00 am ET
Protea Expands Clinical Study for New Melanoma Test
MORGANTOWN, W.Va., Aug. 22, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") announced today that it has expanded its clinical research study for its new molecular imaging test for the differential diagnosis of malignant melanoma. The study has now surpassed 250 patient samples.
Aug 08, 2017 09:00 am ET
Protea Announces Research Agreement with Mass General Hospital
MORGANTOWN, W. Va, Aug. 8, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") announced today that it had entered into a Collaboration Research Agreement with the Vaccine and Immunotherapy Center (VIC), Division of the Massachusetts General Hospital (MGH) and Harvard Medical School. The goal is to co-develop a new diagnostic methodology that will provide cancer cell molecular profiles, including the distribution of drugs within cancer cells and molecular response indicators, to improve patient treatment and outcomes.
Jul 12, 2017 09:00 am ET
Protea announces new test methods for therapeutic antibodies
MORGANTOWN, W.Va., July 12, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") announced that it has integrated its therapeutic antibody analytical methods with new software developed by its partner, Protein Metrics, to automate the detailed analysis of the antibody's structure. The results were presented at the 65th American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics recently held in Indianapolis, Indiana.
Jun 21, 2017 09:30 am ET
Protea introduces new molecular imaging technology
MORGANTOWN, W.Va., June 21, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") announced its development of new technology that enables the direct molecular imaging of the distribution of metabolites and peptides in human clinical tissue samples. The results were presented by Dr. Erin Seeley, Principal Scientist at Protea, at the 65th Annual Meeting of the American Society for Mass Spectrometry and Allied Topics, June 4-8, held in Indianapolis, Indiana.
May 04, 2017 09:30 am ET
Protea and Proteos Announce Co-Marketing Agreement
MORGANTOWN, W.Va. and KALAMAZOO, Mich., May 4, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") and Proteos, Inc. ("Proteos") announced today that they have entered into a joint co-marketing agreement. This mutual partnership allows Protea to combine Proteos' protein production capabilities alongside Protea's proprietary bioanalytical services, and allows Proteos to market and promote Protea's proprietary bioanalytical services with their custom protein production services.
Apr 18, 2017 09:00 am ET
Protea Announces 2016 Year End Results
MORGANTOWN, W.Va., April 18, 2017 /PRNewswire/ -- Protea Biosciences Group, Inc. (OTCQB: PRGB) ("Protea") released its FY2016 results, reporting total revenue of $2,446,795, an increase of 31% over FY2015 revenue of $1,861,802. The revenue growth came primarily from its core bioanalytical services business, which grew to $1,778,006 in FY2016, an increase of 91% over FY2015 revenue of $929,076. Q4 Revenue was $869,786, an increase of 47% over Q4 2015 Revenue of $590,367.
Oct 19, 2016 08:30 am ET
LAESI® technology used in antibacterial research
MORGANTOWN, W.Va., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) (“Protea”) announced today the use of the Company’s proprietary LAESI technology to provide rapid profiling of a bacteria’s resistance to antibiotics....
Aug 16, 2016 08:30 am ET
Protea Announces Second Quarter 2016 Results
MORGANTOWN, W.Va., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) (“Protea”) released its Q2 2016 results today, reporting revenue of $581,764, a 20% increase over revenue reported for the first quarter of 2016, and revenue for the first six months of 2016 of $1,057,102, an increase of 20% over the first six months of 2015....
May 16, 2016 08:00 am ET
Protea Announces First Quarter 2016 Results
MORGANTOWN, W. Va., May 16, 2016 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCQB:PRGB) (“Protea”) released its Q1 2016 results today, reporting revenue of $475,338, a 22% increase over the revenue reported for the first quarter of 2015. Revenue increases were posted for all business lines....
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.